Psyence BioMed sets up US ibogaine subsidiary
Rhea-AI Filing Summary
Psyence Biomedical Ltd. (PBM) announced the formation of Texas Ibogaine Research Corporation (TIRC), a Texas-based subsidiary created to coordinate its U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development. TIRC is intended to be the dedicated U.S. vehicle for regulated ibogaine development.
Subject to definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, in which Psyence BioMed holds an ownership interest, and will be financed by Psyence BioMed. Jody Aufrichtig will serve as Chief Executive Officer of both Psyence BioMed and TIRC, with Dr. John Thorne as project lead. The company highlights that ibogaine remains a controlled substance and is not approved for therapeutic use, and it outlines regulatory, financing and policy risks that could affect the planned activities.
Positive
- None.
Negative
- None.
Key Figures
Press release date: September 14, 2026
Executive Order date: April 18, 2026
Fiscal year-end referenced: March 31, 2026
+1 more
4 metrics
Press release date
September 14, 2026
Date Psyence BioMed announced formation of Texas Ibogaine Research Corporation
Executive Order date
April 18, 2026
Date of U.S. Executive Order directing federal agencies to accelerate relevant neuroplastogen research
Fiscal year-end referenced
March 31, 2026
Fiscal year-end for the Annual Report on Form 20-F whose risk factors are cited
Company phone number
+1 416-477-1708
Contact phone number provided for Psyence Biomedical Ltd.
Key Terms
neuroplastogen, investigational new drug application, controlled substance, Good Manufacturing Practice, +1 more
5 terms
neuroplastogen medical
"a biopharmaceutical company developing nature-derived neuroplastogen therapeutics"
A neuroplastogen is a drug or compound designed to boost the brain’s ability to rewire and form new connections, enhancing recovery or adaptation after injury, stress, or disease. For investors, these molecules matter because they target underlying brain repair processes rather than just masking symptoms, offering the potential for durable benefits in conditions like depression, neurodegeneration, or cognitive decline—akin to giving a tired garden fresh tools to regrow and reshape itself.
investigational new drug application regulatory
"support a potential U.S. development program and any future investigational new drug application"
An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.
controlled substance regulatory
"the continuing status of ibogaine as a controlled substance"
A controlled substance is a drug or chemical whose manufacture, possession, use and distribution are restricted by government law because of potential for abuse, addiction or harm. For investors it matters because these rules shape a company’s ability to sell products, obtain licenses, win approvals and avoid fines or criminal risk — like a speed limit that constrains how fast a business can grow or exposes it to penalties if violated.
Good Manufacturing Practice technical
"operates from an ISO 22000 and GMP-compliant facility"
Good manufacturing practice (GMP) are the rules and routines companies must follow to make products consistently safe and effective, covering everything from equipment and cleanliness to staff training and recordkeeping. For investors, GMP compliance signals lower risk of product failures, regulatory fines, production stoppages or costly recalls—like a reliable recipe and tidy kitchen that help ensure every batch turns out the same and customers stay satisfied.
forward-looking statements regulatory
"This communication contains “forward-looking statements” within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Psyence Biomedical Ltd. (PBM) announce in this Form 6-K?
Psyence Biomedical Ltd. announced the formation of Texas Ibogaine Research Corporation (TIRC), a Texas-based company created to coordinate its U.S. ibogaine development, including pharmaceutical-grade supply, regulatory engagement and potential clinical development activities.
What is the purpose of Texas Ibogaine Research Corporation for PBM?
Texas Ibogaine Research Corporation is intended as PBM’s dedicated U.S. vehicle for regulated ibogaine development, coordinating rights, manufacturing arrangements, regulatory documentation and any future investigational new drug application within a single U.S. entity.
How is Psyence BioMed’s relationship with PsyLabs described in the filing?
Psyence BioMed holds an ownership interest in PsyLabs, a neuroplastogen active pharmaceutical ingredient developer. Subject to definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs.
Who will lead Texas Ibogaine Research Corporation for PBM?
Jody Aufrichtig, Chief Executive Officer of Psyence BioMed, will also serve as Chief Executive Officer of TIRC. Dr. John Thorne has been appointed project lead for Texas Ibogaine Research Corporation.
What regulatory status and risks around ibogaine does PBM highlight?
Psyence BioMed states that ibogaine remains a controlled substance, is not approved for therapeutic use, and its safety and efficacy have not been established. It highlights risks from potential changes in law, regulation, enforcement priorities and clinical and approval uncertainties.
How does PBM plan to support TIRC’s operations?
Psyence BioMed expects to provide TIRC with technical, legal, administrative and financial support through existing internal resources, with corporate oversight from Chief Financial Officer Warwick Corden-Lloyd and the company’s in-house legal function.
What future steps does PBM expect for TIRC and U.S. ibogaine development?
Expected next steps include completing definitive licensing arrangements, progressing regulatory engagement, and developing manufacturing and clinical plans to support a potential U.S. development program, all subject to applicable laws, regulatory requirements and available development pathways.
AI-generated analysis. How Rhea-AI works. Not financial advice.
